|
Jul 24
|
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
|
|
Jul 1
|
INmune slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss
|
|
Jun 30
|
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 30
|
Traders Assess Potential US-Canada Trade Deal, Lifting US Equity Futures Pre-Bell
|
|
Jun 30
|
INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results
|
|
Jun 30
|
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
|
|
Jun 28
|
INmune Bio's US$24m Market Cap Fall Books Insider Losses
|
|
Jun 27
|
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 26
|
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
|
|
Feb 20
|
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28%
|
|
Feb 12
|
INmune Bio price target raised to $23 from $22 at Scotiabank
|
|
Feb 12
|
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
|
|
Feb 10
|
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
|
Nov 13
|
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
|
|
Oct 9
|
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs
|
|
Sep 30
|
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
|
|
Sep 26
|
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
|
|
Jul 29
|
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
|
|
Jul 25
|
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
|
|
Jul 23
|
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
|